The objective of the PHARMGen study is to examine the impact of diabetes-associated genetic variants on response to medications commonly used in the treatment of type 2 diabetes. This study tracks the changes in HbA1c, a measure of glucose levels, during sulfonylurea or metformin monotherapy in a real-world cohort of retrospectively ascertained diabetes patients. The study will enroll 2,000 patients across several clinical sites: Massachusetts General Hospital, Brigham and Women’s Hospital, Harvard Vanguard Medical Associates, and NorthShore (Chicago).
PHARMGen researchers hypothesize that comparing the genetic profiles of patients in whom treatment is effective or not effective will help characterize the mechanism of diabetes-associated variants and identify individuals more likely to benefit from specific modes of therapy. The study will also identify genetic variants that influence response to sulfonylurea or metformin monotherapy.